[ad_1] (Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc’s treatment for depression in patients with an inadequate response to standard antidepressant …
Read More »
[ad_1] Alkermes plc. (ALKS – Free Report) reported adjusted earnings of 7 cents per share in the third quarter of 2018, while the Zacks Consensus Estimate was a loss of 6 cents. …
Read More »
[ad_1] VERONA PHARMA P / S (NASDAQ: VRNA) and Alkermes (NASDAQ: ALKS) are both medical companies, but what is the best deal? We will compare the two companies based on the strength …
Read More »